Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Ascletis Pharma, Inc. ( (HK:1672) ) just unveiled an announcement.
Ascletis Pharma Inc. held its Annual General Meeting on May 22, 2025, where all proposed resolutions were passed, including the re-election of directors and the re-appointment of KPMG as auditors. The company granted mandates to the board to issue and repurchase shares, reflecting strong shareholder support and potentially enhancing its capital management strategy.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative drugs for the treatment of liver diseases, viral infections, and cancer. The company is listed on the Hong Kong Stock Exchange under the stock code 1672.
Average Trading Volume: 7,167,514
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.11B
See more data about 1672 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue